Success Metrics

Completion Rate

0%(0/4)

Active Trials

0(0%)

Terminated

4(80%)

Phase Distribution

Ph phase_1

80%

Ph phase_3

20%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution5 total trials

Phase 1Safety & dosage

4(80.0%)

Phase 3Large-scale testing

1(20.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

0.0%

0 of 5 finished

Non-Completion Rate

100.0%

5 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Terminated(5)

Detailed Status

Terminated4

Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

0.0%

Most Advanced

Phase 3

Trials by Phase

Phase 14 (80.0%)

Phase 31 (20.0%)

Trials by Status

terminated480%

withdrawn120%

Recent Activity

0 active trials

Showing 5 of 5

terminatedphase_1

AVB-S6-500 and Durvalumab in Treating Patients With Platinum-Resistant or Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

NCT04019288

withdrawnphase_1

AVB-500 (Batiraxcept) in Combination With Paclitaxel in Recurrent High Grade Uterine Cancer

NCT05826015

terminatedphase_3

Batiraxcept (AVB-S6-500)/Placebo in Combination With Paclitaxel in Patients With Platinum-Resistant Recurrent Ovarian Cancer

NCT04729608

terminatedphase_1

Safety and Efficacy Study of AVB-S6-500 (Batiraxcept) in Patients With Advanced or Metastatic Clear Cell Renal Cell Carcinoma

NCT04300140

terminatedphase_1

Safety and Efficacy Study of AVB-S6-500 (Batiraxcept) in Patients With Advanced Pancreatic Adenocarcinoma

NCT04983407

Clinical Trials (5)

Showing 5 of 5 trials

NCT04019288Phase 1

AVB-S6-500 and Durvalumab in Treating Patients With Platinum-Resistant or Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Terminated

NCT05826015Phase 1

AVB-500 (Batiraxcept) in Combination With Paclitaxel in Recurrent High Grade Uterine Cancer

Withdrawn

NCT04729608Phase 3

Batiraxcept (AVB-S6-500)/Placebo in Combination With Paclitaxel in Patients With Platinum-Resistant Recurrent Ovarian Cancer

Terminated

NCT04300140Phase 1

Safety and Efficacy Study of AVB-S6-500 (Batiraxcept) in Patients With Advanced or Metastatic Clear Cell Renal Cell Carcinoma

Terminated

NCT04983407Phase 1

Safety and Efficacy Study of AVB-S6-500 (Batiraxcept) in Patients With Advanced Pancreatic Adenocarcinoma

Terminated

All 5 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 5